With 1.23 million shares changed hands, the volume of the stock remained lighter than its average volume of 1.75 million shares. During the session, the Biotechnology company that operates in wider Healthcare sector, reached to the highest price of $2.34 whereas the lowest price it dropped to was $2.1. The 52-week range on LITS shows that it touched its highest point at $9.00 and its lowest point at $1.46 during that stretch. It currently has a 1-year price target of $22.67. LITS paid its most recent dividend on 1700092800, while the ex-dividend date for that was 1700092800. Beta for the stock currently stands at 0.31.
Price Performance and Earnings:
Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of LITS was down-trending over the past week, with a drop of -17.31%, but this was down by -26.62% over a month. Three-month performance dropped to -29.97% while six-month performance rose 14.97%. The stock lost -12.60% in the past year, while it has lost -19.78% so far this year.
Float and Shares Shorts:
At present, 35.66 million LITS shares are outstanding with a float of 30.42 million shares on hand for trading. On 2025-09-30, short shares totaled 0.36 million, which was 101.99999 higher than short shares on 1756425600. In addition to Mr. Justin J. File CPA as the firm’s Acting CEO, CFO & Corporate Secretary, Ms. Anne Frese serves as its Chief People Officer.
An Overview of Recent Financials:
Understanding a company as a customer does not mean you will understand it as an investor. The wise investor uses quantitative research to analyze metrics such as revenue, net income, and earnings. In its fiscal quarter reported on 2025-06-30, LITS reported revenue of $0.0 and operating income of -$2878000.0. The EBITDA in the recently reported quarter was -$2878000.0 and diluted EPS was $nan.
